Company news
Vistagen Therapeutics, Inc. news in 2025
Vistagen Therapeutics, Inc.'s news releases, calls and decks from 2025, newest first.
Vistagen Announces Topline Results from PALISADE-3 Phase 3 Public Speaking Challenge Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder
December 17, 2025
Vistagen Appoints Nick Tressler as Chief Financial Officer
December 1, 2025
Vistagen Reports Findings on PH80’s Brain and Autonomic Effects in Women with Menopausal Hot Flashes at The Menopause Society 2025 Annual Meeting
November 26, 2025
Vistagen Reports Fiscal Year 2026 Second Quarter Financial Results and Provides Corporate Update
November 13, 2025
Vistagen to Report Fiscal Year 2026 Second Quarter Results and Host Corporate Update Conference Call on November 13, 2025
November 10, 2025
Vistagen to Participate in Stifel Healthcare Conference 2025
November 5, 2025
Vistagen Completes PALISADE-3 Phase 3 Public Speaking Challenge Study for the Acute Treatment of Social Anxiety Disorder
November 3, 2025
Vistagen Appoints Paul Edick to its Board of Directors
October 29, 2025
Vistagen to Present at The Menopause Society 2025 Annual Meeting
October 16, 2025
Vistagen to Present at the TD Cowen 5th Annual Novel Mechanisms in Neuropsychiatry & Epilepsy Summit
September 9, 2025
Vistagen Reports Fiscal Year 2026 First Quarter Financial Results and Corporate Update
August 7, 2025
Vistagen to Report Fiscal Year 2026 First Quarter Results and Host Corporate Update Conference Call on August 7, 2025
July 31, 2025
Vistagen to Present at the BTIG Virtual Biotechnology Conference
July 24, 2025
Vistagen Honored for Outstanding Workplace Culture and Mental Health Leadership
July 15, 2025
Vistagen Appoints Elissa Cote as Chief Corporate Development Officer
June 25, 2025
Vistagen Reports Fiscal Year 2025 Financial Results and Provides Corporate Update
June 17, 2025
Vistagen to Report Fiscal Year 2025 Financial Results and Host Corporate Update Conference Call on June 17, 2025
June 12, 2025
Vistagen on Track to Deliver Topline Data From Fasedienol PALISADE-3 Phase 3 Trial for Acute Treatment of Social Anxiety Disorder in the Fourth Quarter of This Year
June 2, 2025
Vistagen to Present at the Jefferies 2025 Global Life Sciences Conference New York
May 28, 2025
Vistagen to Present at the 2025 American Society of Clinical Psychopharmacology Conference
May 23, 2025
Vistagen Presents New Research on the Impact of Social Anxiety Disorder at The Anxiety and Depression Association 2025 Conference
April 17, 2025
Vistagen to Present at the 2025 Anxiety and Depression Association Conference
March 19, 2025
Vistagen to Participate in Stifel 2025 Virtual CNS Forum
March 4, 2025
Vistagen to Participate in the 45th Annual TD Cowen Healthcare Conference
February 20, 2025
Vistagen Reports Fiscal Year 2025 Third Quarter Financial Results and Corporate Update
February 12, 2025
Vistagen Receives U.S. Patent for AV-101 to Treat Neuropathic Pain
February 4, 2025
Vistagen Announces Positive Results from Exploratory Phase 2A Study of PH284 in Cancer Cachexia
January 13, 2025
Vistagen Initiates Fasedienol Repeat Dose Study for the Acute Treatment of Social Anxiety Disorder
January 9, 2025
Calls in 2025
- Vistagen Therapeutics (NASDAQ:VTGN) Q2 2026 Earnings Call
Nov 13, 2025
Transcript - Vistagen Therapeutics (NASDAQ:VTGN) Q1 2026 Earnings Call
Aug 7, 2025
Transcript - Vistagen Therapeutics (NASDAQ:VTGN) Q4 2025 Earnings Call
Jun 17, 2025
Transcript - Vistagen Therapeutics (NASDAQ:VTGN) Q3 2025 Earnings Call
Feb 13, 2025
Transcript
Decks in 2025
- Investor Presentation (August 2025)
Investor deck · 59 slides · Aug 7, 2025
- Investor Presentation (June 2025)
Investor deck · 59 slides · Jun 2, 2025
- TD Cowen 45th Annual Health Care Conference (March 2025)
Conference · 34 slides · Mar 6, 2025
- Investor Presentation (February 2025)
Investor deck · 59 slides · Feb 13, 2025